Autolus Therapeutics

NASDAQ: AUTL · Real-Time Price · USD
1.73
-0.12 (-6.49%)
At close: Aug 15, 2025, 3:59 PM
1.76
1.73%
After-hours: Aug 15, 2025, 07:55 PM EDT

Autolus Therapeutics Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022 Q2 2022 Q1 2022 Q4 2021 Q3 2021 Q2 2021 Q1 2021
Period Ending Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021
Revenue
8.98M 29K n/a n/a 10.09M 1.77M 406K n/a 1.29M 3.83M 2.37M n/a 166K 823K 236K 1.51M 269K
Cost of Revenue
17.95M n/a 223K 1.9M 1.81M 1.77M 382K 1.51M 1.9M 27.41M 37.63M 1.92M 2.07M 39.63M 2.45M 2.24M 1.66M
Gross Profit
-8.97M -13.44M -223K -1.9M 8.29M n/a 24K -1.51M -607K -23.59M -35.26M -1.92M -1.9M -38.81M -2.21M -737K -1.39M
Operating Income
-65.24M -75.86M -67.88M -58.93M -38.76M -40.89M -48.23M -43.98M -35.11M -28.09M -47.07M -47.72M -40.9M -47.6M -40.35M -37.72M -38.53M
Interest Income
6.14M 7.45M 8.32M 9.66M 6.93M 3.01M 3.65M 3.4M 3.45M 1.43M 165K 89K 28K 149K 28K 42K 44K
Pretax Income
-67.94M -26.14M -82.07M -58.22M -52.7M -64.81M -50.79M -49.02M -43.78M -32.07M -48.92M -49.53M -42.69M -48.09M -39.38M -39.53M -38.99M
Net Income
-70.16M -27.61M -82.09M -58.27M -52.69M -77.17M -45.85M -45.55M -39.81M -26.95M -42.77M -42.06M -37.06M -41.67M -33.99M -33.17M -33.27M
Selling & General & Admin
29.53M 33.68M 27.33M 21.9M 16.37M 13.95M 10.61M 11.12M 9.28M 7.41M 8.23M 8.27M 7.99M 7.59M 8.3M 7.24M 8.74M
Research & Development
26.73M 30.83M 40.32M 36.61M 30.67M 25.16M 37.24M 36.74M 31.34M 32.19M 37.63M 38.21M 33.96M 39.63M 32.29M 32.13M 30.73M
Other Expenses
n/a n/a n/a n/a n/a n/a n/a 482K 782K 6.25M -3.74M -1.33M -166K -86K 951K -1.85M 838K
Operating Expenses
56.27M 64.51M 67.65M 58.52M 47.04M 39.11M 47.85M 47.86M 40.63M 39.6M 45.86M 46.48M 41.78M 47.87M 40.35M 39.23M 39.47M
Interest Expense
10.14M n/a 10.69M 10.17M 19.27M 30.13M 5.01M 5.02M 4.91M 3.46M 1.85M 1.81M 1.79M 1.1M n/a n/a n/a
Selling & Marketing Expenses
n/a n/a n/a n/a -1.81M -1.77M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Cost & Expenses
74.22M 75.67M 67.88M 58.52M 48.85M 40.89M 47.85M 47.86M 40.63M 39.6M 45.86M 46.48M 41.78M 47.87M 40.35M 39.23M 39.47M
Income Tax Expense
2.23M 1.46M 22K 51K -8K 12.36M -4.94M -3.47M -3.97M -5.12M -6.15M -7.47M -5.62M -6.43M -5.38M -6.36M -5.72M
Shares Outstanding (Basic)
266.13M 266.13M 266.08M 266.03M 222.17M 174.03M 173.98M 173.86M 173.83M 117.18M 90.99M 90.93M 90.91M 72.9M 72.9M 70.83M 62.45M
Shares Outstanding (Diluted)
266.13M 266.13M 266.08M 266.03M 222.17M 174.03M 173.98M 173.86M 173.83M 117.18M 91.24M 90.93M 90.91M 72.9M 72.9M 70.83M 62.45M
EPS (Basic)
-0.26 -0.11 -0.31 -0.22 -0.24 -0.44 -0.26 -0.26 -0.23 -0.23 -0.47 -0.46 -0.41 -0.57 -0.47 -0.47 -0.53
EPS (Diluted)
-0.26 -0.11 -0.31 -0.22 -0.24 -0.44 -0.26 -0.26 -0.23 -0.23 -0.47 -0.46 -0.41 -0.57 -0.47 -0.47 -0.53
EBITDA
-65.24M -54.9M -69.45M -46.15M -31.62M -32.91M -44.4M -38.98M -33.48M -26.9M -45.28M -45.8M -38.83M -45.5M -36.93M -37.29M -37.33M
EBIT
-57.79M -56.98M -71.39M -48.05M -33.43M -34.68M -45.77M -40.49M -34.92M -28.61M -47.07M -47.72M -40.9M -47.6M -39.38M -39.53M -38.99M
Depreciation & Amortization
2.28M 2.08M 1.94M 1.9M 1.81M 1.77M 1.38M 1.51M 1.9M 1.71M 1.79M 1.92M 2.07M 2.19M 2.45M 2.24M 1.66M